Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens
about
Targeted therapies with companion diagnostics in the management of breast cancer: current perspectivesBiomarkers for glioma immunotherapy: the next generationMolecular Technologies in the Clinical Diagnostic LaboratoryAdvances in the Molecular Analysis of Breast Cancer: Pathway Toward Personalized MedicineCombining Radiation Therapy with Immune Checkpoint Blockade for Central Nervous System MalignanciesValidation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validationHormonal Modulation of Breast Cancer Gene Expression: Implications for Intrinsic Subtyping in Premenopausal WomenTailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015A novel miRNA-based predictive model for biochemical failure following post-prostatectomy salvage radiation therapyMolecular portraits: the evolution of the concept of transcriptome-based cancer signaturesFuture microfluidic and nanofluidic modular platforms for nucleic acid liquid biopsy in precision medicine.Single-Patient Molecular Testing with NanoString nCounter Data Using a Reference-Based Strategy for Batch Effect Correction.RNA Sequencing of Formalin-Fixed, Paraffin-Embedded Specimens for Gene Expression Quantification and Data MiningLimitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer.An international reproducibility study validating quantitative determination of ERBB2, ESR1, PGR, and MKI67 mRNA in breast cancer using MammaTyper®Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assays.Preanalytical variables and performance of diagnostic RNA-based gene expression analysis in breast cancer.Emerging gene-based prognostic tools in early breast cancer: First steps to personalised medicine.Direct detection and drug-resistance profiling of bacteremias using inertial microfluidicsDevelopment and verification of the PAM50-based Prosigna breast cancer gene signature assayPrior knowledge transfer across transcriptional data sets and technologies using compositional statistics yields new mislabelled ovarian cell line.Technical validation of an RT-qPCR in vitro diagnostic test system for the determination of breast cancer molecular subtypes by quantification of ERBB2, ESR1, PGR and MKI67 mRNA levels from formalin-fixed paraffin-embedded breast tumor specimens.Comprehensive comparison of molecular portraits between cell lines and tumors in breast cancer.Development of prognostic signatures for intermediate-risk papillary thyroid cancerMorphologic and Molecular Characteristics of Mixed Epithelial Ovarian Cancers.Clinical Application of Prognostic Gene Expression Signature in Fusion Gene-Negative Rhabdomyosarcoma: A Report from the Children's Oncology GroupUsing prior knowledge from cellular pathways and molecular networks for diagnostic specimen classification.Genomic markers of panitumumab resistance including ERBB2/ HER2 in a phase II study of KRAS wild-type (wt) metastatic colorectal cancer (mCRC).Folic-acid metabolism and DNA-repair phenotypes differ between neuroendocrine lung tumors and associate with aggressive subtypes, therapy resistance and outcome.Integrated Analysis Identifies Molecular Signatures and Specific Prognostic Factors for Different Gastric Cancer Subtypes.NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies.Finger stick blood collection for gene expression profiling and storage of tempus blood RNA tubes.Pathologic diagnosis, immunohistochemistry, multigene assays and breast cancer treatment: progress toward "precision" cancer therapy.The histone chaperone HJURP is a new independent prognostic marker for luminal A breast carcinoma.Indications for prognostic gene expression profiling in early breast cancer.An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors.Biomarker assessment and molecular testing for prognostication in breast cancer.NanoString, a novel digital color-coded barcode technology: current and future applications in molecular diagnostics.Molecular nephropathology: ready for prime time?An mRNA Gene Expression-Based Signature to Identify FGFR1-Amplified Estrogen Receptor-Positive Breast Tumors.
P2860
Q26768119-06E81BB5-FC35-4728-AADA-20437BE8B73AQ26825496-391E11B4-1EDA-42E0-BF32-EE53FB42483AQ26996463-814D51D3-0C87-47F6-B2A6-663BA64AE422Q27001994-056084B6-19EF-4846-8E5E-7F052F7C0460Q28072007-90B88680-DE9D-412A-853F-085C8AF7C4D4Q28075719-A08DABB0-49C1-4C24-B94C-5E6E89E48625Q28077637-978F65D0-618A-44AF-935D-48E5ABA0188AQ28085062-CFC2B9C5-35CF-4C1C-9DF4-3A86E751BBD5Q28543958-19B18642-C133-4684-8A20-A10396CD0D17Q28607220-48E1C15C-72FA-4938-92DB-AC015189DC36Q30357091-A5363A8D-9C3F-442C-B37C-16FF15E385AFQ31081473-A7F4286B-8BC1-45C2-832F-A2479756CDBDQ31138624-610FC862-8859-483D-B408-C422EBB122A0Q33591751-924537E7-2354-4128-824A-E3986525C50CQ33660598-DCF57CFD-0443-4B99-8844-F301C0CA370AQ33834198-7494B2FB-084C-4F4C-BBB4-28E961945EA5Q34271033-D74F1B78-A800-4A1C-8EA0-2B0ECBB93664Q34657656-7332DFE6-7082-480F-8495-C53F63FD00E1Q35624778-8F848462-AFB1-4D37-9178-16D0EF4B5A6EQ35752868-7C4A7CCA-0F22-481D-8649-A60CDA809FF4Q36063561-C000E7A2-DB69-45AA-8BE2-10B960A39D57Q36070547-A903686E-359D-4B8B-834B-4CC8AF3F628AQ36111215-72695EB0-25BF-4069-83C1-40AC934E6D3DQ36134855-58E2F5FB-3E34-4216-8FC5-52464B828925Q36157106-9ED28323-18D8-41DA-93E3-8C87777C7A3AQ36175120-EE0045AC-C957-455D-8D52-4F2B682ABCC9Q36910040-A22F967F-87F9-4F6F-B58B-81DDF27CD447Q37109905-09AD7F6F-E034-4B45-B608-953C20BB394BQ37190264-BA9D5034-0D96-4113-A957-3E8BB3A09799Q37543800-D2C7BF6A-8A2D-41E7-BBAD-D5031422DE68Q37590339-060D6D4A-A0C9-4142-A343-44E19BD953A6Q37709709-0FF1C3F9-EBE7-4288-BA91-BE026463F8A9Q38272730-117A119F-2A19-4ED8-A8D8-0AF4FEE8B770Q38302260-BDBD8EB8-702B-4B52-8C4F-B0E7C14E3BF4Q38451798-02DD8F56-3531-4B27-9647-278C51F57ACFQ38603909-5F7FFA7B-FBEE-4A18-9DA2-B3922BF9C6ECQ38696790-2537CDB4-44E6-4CE3-A6B6-0546770241C4Q38787248-D8CCD6BB-058B-477C-999C-9ED7BC48B05AQ39001991-4090B32E-8736-47CE-94D5-CEF585283ACAQ40417660-AA264893-EF57-4456-9079-3B5D8B787BC5
P2860
Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Analytical validation of the P ...... mbedded breast tumor specimens
@ast
Analytical validation of the P ...... mbedded breast tumor specimens
@en
Analytical validation of the P ...... bedded breast tumor specimens.
@nl
type
label
Analytical validation of the P ...... mbedded breast tumor specimens
@ast
Analytical validation of the P ...... mbedded breast tumor specimens
@en
Analytical validation of the P ...... bedded breast tumor specimens.
@nl
prefLabel
Analytical validation of the P ...... mbedded breast tumor specimens
@ast
Analytical validation of the P ...... mbedded breast tumor specimens
@en
Analytical validation of the P ...... bedded breast tumor specimens.
@nl
P2093
P2860
P356
P1433
P1476
Analytical validation of the P ...... mbedded breast tumor specimens
@en
P2093
Brett Wallden
Carl Schaper
Dongxia Gao
Garrett Barry
James Storhoff
Malini Maysuria
Naeem Dowidar
Sean Ferree
Shuzhen Liu
Torsten Nielsen
P2860
P2888
P356
10.1186/1471-2407-14-177
P407
P577
2014-03-13T00:00:00Z
P5875
P6179
1024727892